Accelerated Computational Drug Discovery
Built to support cross-disciplinary workflows, NVIDIA Clara™ Discovery combines the power of accelerated computing, AI, and machine learning to supercharge the entire drug development process, unlocking the potential to bring life-saving drugs to market faster.
Clara Discovery is a collection of frameworks, applications, and AI models enabling GPU-accelerated drug discovery, with support for research in genomics, proteomics, microscopy, virtual screening, computational chemistry, visualization, clinical imaging, and natural language processing (NLP). Browse these tools in the NGC™ catalog, NVIDIA’s hub for GPU-optimized software.
Clara Discovery is optimized to run on NVIDIA DGX™ A100, the world’s most advanced AI system delivering five petaFLOPS of performance. Purpose-built for all accelerated computing workloads at scale, DGX A100 provides researchers the fastest time to solution and IT a unified, easy-to-deploy infrastructure to support the next-generation of drug discovery.
View HPC Application Performance
View Deep Learning Framework Performance
CPU vs GPU: NVIDIA Clara Parabricks, Relion, Autodock-GPU, NVIDIA RAPIDS, Amber, NAMD, VMD, Gromacs, NVIDIA Clara Imaging, BERT Training
Going online in late 2020, NVIDIA will build the UK’s most powerful supercomputer using NVIDIA DGX SuperPOD™ to support the entire ecosystem of cross-industry healthcare researchers from universities to startups to research institutions.
To accelerate drug and vaccine discoveries, GSK and NVIDIA are partnering together on an AI-powered lab that will unlock genetic and clinical data with increased precision and scale.
Bringing together 17 partners, including 10 leading pharmaceutical companies, MELLODDY will use federated learning techniques and NVIDIA GPUs to leverage the world’s largest collaborative drug compound dataset for AI training without sacrificing data privacy.